London · Delayed Price · Currency is GBP · Price in GBX Tristel Earnings Call Transcripts
Fiscal Year 2026
-
Record interim revenue and profit growth driven by strong UK, European, and U.S. performance, with robust cash generation and continued investment in commercial expansion. U.S. market momentum accelerates, supported by clinical guideline endorsements and strategic partnerships.
Fiscal Year 2025
-
Double-digit revenue and profit growth were achieved, with strong margins and a 5% dividend increase. U.S. expansion, new product launches, and manufacturing efficiencies support a positive outlook, with double-digit growth targeted through 2030.
-
Strong financial growth continues, driven by geographic expansion, U.S. market entry, and product innovation. Focus remains on high-margin infection prevention niches, digital transformation, and leveraging customer advocacy for further penetration.
-
Revenue grew 8% to £22.6m and adjusted profit before tax rose 19% to £4.9m, with strong cash generation and no debt. Growth is driven by medical device decontamination, with the US market and new product launches providing significant future opportunities.